Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 1167

Next Previous
X
Search
Drug Profile

HRS 1167

Alternative Names: HRS-1167; M-9466

Latest Information Update: 30 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 23 Jul 2024 Fudan University plans a phase II trial for HER2-negative breast cancer (Neoadjuvant therapy, Combination therapy) in China in July 2024 (NCT06516289)
  • 19 Jul 2024 EMD Serono Research & Development Institute in collaboration with Merck KGaA plans a phase I trial for Solid tumours and Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, In combination therapy) in the US and Germany (PO)(NCT06509906)
  • 02 Jul 2024 Phase-II clinical trials in Solid tumours (Late-stage disease, Combination therapy) (PO), prior to July 2024 (Jiangsu Hengrui Medicine Co pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top